| 000 | 00000nam 2200000za 4500 |
| 001 | 9.849733 |
|---|
| 003 | CaOODSP |
|---|
| 005 | 20221107154004 |
|---|
| 007 | cr ||||||||||| |
|---|
| 008 | 180109s2018 onca o f000 0 eng d |
|---|
| 020 | |a9780660244754|z9780660244778 |
|---|
| 040 | |aCaOODSP|beng |
|---|
| 043 | |an-cn--- |
|---|
| 086 | 1 |aNR16-196/2018E-PDF |
|---|
| 110 | 2 |aNational Research Council Canada. |
|---|
| 245 | 10|aAntibody generation, characterization, and optimization |h[electronic resource]. |
|---|
| 260 | |a[Ottawa] : |bNational Research Council Canada, |c2018. |
|---|
| 300 | |a[2] p. : |bcol. ill. |
|---|
| 500 | |aIssued also in French under title: Génération, caractérisation et optimisation d’anticorps. |
|---|
| 500 | |aCaption title. |
|---|
| 500 | |a"February 2018." |
|---|
| 520 | |a"The NRC’s Human Health Therapeutics Research Centre can help you develop therapeutic, diagnostic, and carrier antibodies against cancer, infectious diseases, central nervous system (CNS) diseases, and other indications. We offer R&D services in antibody generation against a wide variety of target classes, as well as antibody characterization and lead optimization"--P. [1]. |
|---|
| 530 | |aIssued also in print format. |
|---|
| 693 | 4|aMonoclonal antibodies |
|---|
| 693 | 4|aImmunotechnology |
|---|
| 775 | 08|tGénération, caractérisation et optimisation d’anticorps |w(CaOODSP)9.849734 |
|---|
| 776 | 0#|tAntibody generation and optimization |w(CaOODSP)9.849737 |
|---|
| 856 | 40|qPDF|s195 KB|uhttps://publications.gc.ca/collections/collection_2018/cnrc-nrc/NR16-196-2018-eng.pdf |
|---|